Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech

Genenta Science SpA Sponsored ADR ( (GNTA) ) has issued an update.

On April 22, 2026, Genenta Science S.p.A. signed a Purchase and Investment Agreement to acquire majority control of Sòphia High Tech, an Italian aerospace and defense engineering manufacturer that supplies critical components for European space and defense programs. The deal underpins Genenta’s shift from pure biotech toward becoming a strategic industrial consolidator across Italy’s national security sectors.

Genenta plans to invest a total of €6.0 million in two tranches, initially taking a 19.9% stake in Sòphia High Tech and later increasing its holding to 51%, subject to conditions including government approvals and certain EBITDA milestones. The capital is expected to help Sòphia High Tech, which reported roughly €6.29 million in 2024 revenue and about €0.96 million in EBITDA, scale capacity, accelerate technology development and deepen market penetration, potentially strengthening Genenta’s position in Europe’s space and defense supply chain.

The most recent analyst rating on (GNTA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.

More about Genenta Science SpA Sponsored ADR

Genenta Science S.p.A., listed on Nasdaq as GNTA, is transitioning from a clinical-stage biotechnology company developing Temferon into a next‑generation strategic consolidator. The group is focusing on privately held Italian businesses in national security–regulated sectors, spanning cybersecurity, defense, aerospace and biotechnology/biosecurity, with an emphasis on technologies tied to Italy’s Golden Power framework.

Average Trading Volume: 1,069,899

Technical Sentiment Signal: Sell

Current Market Cap: $16.17M

For an in-depth examination of GNTA stock, go to TipRanks’ Overview page.